BRAINTREE, Mass., Jan. 24 Haemonetics announcedtoday the decision by its Board of Directors to expand the role of currentChief Executive Officer Brad Nutter to a newly created position that combinesthe roles of CEO and Chairman of the Board. Mr. Nutter's promotion iseffective immediately.
(Photo: http://www.newscom.com/cgi-bin/prnh/20080124/NETH036 )
Ron Gelbman, who will continue in his role as Haemonetics' Lead Director,said "The Company has never been stronger, due in large part to Brad Nutter'spassionate, engaged leadership, and the particularly strong management teamhe's assembled. Since Brad joined the Company in 2003, shareholder valueincreased significantly, quality of earnings strengthened, and the Companybegan executing on a long term Strategic Plan to leverage and expand thebusiness. Brad has also been the architect of the Company's new vision toleverage its global leadership position in blood management solutions for ourcustomers."
Brad Nutter stated, "I am energized by this new role, and enormously proudof the Haemonetics team and what we've accomplished together over the lastfour years. I am even more excited about the opportunities to deliver onexpectations to offer expanded blood management solutions globally, andcontinuing our focus on creating shareholder value."
Haemonetics (NYSE: HAE) is a global healthcare company dedicated toproviding innovative blood management solutions for our customers. Together,our devices and consumables, IT products, and consulting services deliver asuite of business solutions to help our customers improve clinical outcomesand reduce the cost of healthcare for blood collectors, hospitals, andpatients around the world. Our technologies address important medicalmarkets: blood and plasma component collection, the surgical suite, andhospital transfusion services. To learn more about Haemonetics, visit our website at http://www.haemonetics.com.CONTACT: Julie Fallon Tel. (781) 356-9517 Alternate Tel. (617) 320-2401 [email protected]